{
  "source": "PA-Notification-Iclusig.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1043-14\nProgram Prior Authorization/Notification\nMedication Iclusig® (ponatinib)\nP&T Approval Date 2/2013, 7/2013, 8/2013, 2/2014, 2/2015, 2/2016, 12/2016, 11/2017,\n11/2018, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nIclusig (ponatinib) is a kinase inhibitor indicated for the treatment of patients with newly\ndiagnosed Philadelphia chromosome-positive acute Lymphoblastic Leukemia (Ph+ ALL), in\ncombination with chemotherapy, as monotherapy in Ph+ ALL for whom no other kinase\ninhibitors are indicated, or T315I-positive Ph+ ALL. Iclusig is also indicated in chronic phase\n(CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior\nkinase inhibitors, accelerated phase (AP) or blast phase (BP) CML for whom no other kinase\ninhibitors are indicated, and T315I-positive CML (chronic phase, accelerated phase, or blast\nphase).\nThe National Comprehensive Cancer Network (NCCN) also recommends Iclusig for the\ntreatment of myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FGFR1 or\nABL1 rearrangements, and gastrointestinal stromal tumors.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Iclusig will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Chronic Myelogenous / Myeloid Leukemia (CML)\n1. Initial Authorization\na. Iclusig will be approv",
    "lowing criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Chronic Myelogenous / Myeloid Leukemia (CML)\n1. Initial Authorization\na. Iclusig will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of chronic myelogenous/myeloid leukemia (CML)\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. Disease is in the chronic phase\nii. Patient with resistance or intolerance to two or more tyrosine kinase\ninhibitor (TKI) therapies [e.g., imatinib mesylate, Sprycel (dasatinib), or\nTasigna (nilotinib)]\n-OR-\n(b) Confirmed documentation of T315I mutation\n-OR-\n(c) Both of the following:\ni. Disease is in the accelerated or blast phase\nii. No other kinase inhibitors are indicated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iclusig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Iclusig therapy\nAuthorization will be issued for 12 months.\nC. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)\n1. Iclusig will be approved based on the following criterion:\na. Diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia\n(Ph+ALL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iclusig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Iclusig therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nD. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Iclusig will be approved based on both of the following:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with\neosinophilia\n-AND-\n(2) One of the following:\n(a) Patient has a FGFR1 rearrangement\n(b) Patient has an ABL1 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iclusig will be approved based on the following criterion:\n(1) Patient does ",
    "FGFR1 rearrangement\n(b) Patient has an ABL1 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iclusig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Iclusig therapy.\nAuthorization will be issued for 12 months.\nE. Gastrointestinal Stromal Tumors (GIST)\n1. Initial Authorization\na. Iclusig will be approved based on both of the following:\n(1) Diagnosis of gastrointestinal stromal tumor (GIST)\n-AND-\n(2) Disease is one of the following:\n(a) Gross residual disease (R2 resection)\n(b) Unresectable primary disease\n(c) Tumor rupture\n(d) Recurrent/metastatic disease after progression on approved therapies (e.g.\nimatinib, sunitinib, regorafenib, and standard dose ripretinib)\n© 2024 UnitedHealthcare Services, Inc.\n3\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iclusig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Iclusig therapy.\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Iclusig [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc",
    "al and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Iclusig [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March\n2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nSeptember 26, 2024.\nProgram Prior Authorization/Notification - Iclusig (ponatinib)\nChange Control\n2/2014 Updated coverage criteria with new FDA labeling indications.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Added ‘or has failed treatment with’ and ‘at least two or more’ to TKI\nrequirement. Updated references.\n2/2016 Annual review. Increased authorization from 10 months to 12 month.\nAdded ‘used in combination with an induction regimen not previously\n© 2024 UnitedHealthcare Services, Inc.\n4\nused’ to Ph+ALL. Formatting revision. Updated background and\nreferences.\n12/2016 Annual review. Changed Gleevec to imatinib mesylate. Updated\nformatting and references.\n11/2017 Annual review. Removed Acute Lymphoblastic Lymphoma based on\nNCCN recommendations. Updated references.\n11/2018 Annual review. Added use with HyperCVAD (hyper-fractionated\ncyclophosphamide, vincristine, doxorubicin, and dexamethasone,\nalternating with high-dose methotrexate and cytarabine) induction or\nconsolidation and as maintenance therapy in combination with\nvincristine and prednisone with or without methotrexate and\nmercaptopurine and post-hematopoietic stem cell transplant. Updated\nreferences based on NCCN recommendations.\n11/2019 Annual review. Updated references.\n11/2020 Annual review. Updated background to reflect package insert.\nUpdated clinical criteria for Ph+ ALL removing specific drug regimens.\nUpdated NCCN guidelines for Myeloid/Lymphoid Neoplasms in\nbackground and criteria. Updated references.\n11/2021 Annual review. Updated Ph+ALL and CML criteria to reflect package\ninsert and",
    "ug regimens.\nUpdated NCCN guidelines for Myeloid/Lymphoid Neoplasms in\nbackground and criteria. Updated references.\n11/2021 Annual review. Updated Ph+ALL and CML criteria to reflect package\ninsert and NCCN recommendations. Updated background and\nreferences.\n11/2022 Annual review. Updated CML and ALL criteria based on NCCN\nrecommendations. Added state mandate footnote. Updated references.\n11/2023 Annual review. Updated ALL criteria based on NCCN\nrecommendations. Added criteria for GIST based on NCCN\nrecommendations. Updated background and references.\n11/2024 Updated background and references. No changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}